Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg

Dermatologic Surgery

Volumn 30, Issue 12 II, 2004, Pages 1556-1560

  Thiele, Jens J ^b,c   Ziemer, Mirjana ^a   Fuchs, Silke ^a   Elsner, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ADULT; ARTICLE; CASE REPORT; ERBIUM YAG LASER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; LASER SURGERY; LEG; PRIORITY JOURNAL; SKIN BIOPSY; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 11144222540     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30559.x     Document Type: Article

References (33)

1. Gassenmaier A, Pfister H, Hornstein OP. Human papillomavirus 25-related DNA in solitary keratoacanthoma. Arch Dermatol Res 1986;279:73-6.
2. Radakovic-Fijan S, Honigsmann H, Tanew A. Efficacy of topical photodynamic therapy of a giant keratoacanthoma demonstrated by partial irradiation. Br J Dermatol 1999;141:936-8.
3. Cristofolini M, Piscioli F, Zumiani G, et al. The role of etretinate (Tegison; Tigason) in the management of keratoacanthoma. J Am Acad Dermatol 1985;12:633-8.
4. Odom RB, Goette DK, et al. Treatment of keratoacanthomas with intralesional fluorouracil. Arch Dermatol 1978;114:1779-83.
5. Grevelhorster T, Micke O, Hampel G, et al. [High-dose multimodal radiotherapy of confluent destructively growing aggregated keratoacanthoma. 2 case reports]. Strahlenther Onkol 1996;172:395-400.
6. Goldschmidt H, Sherwin WK. Radiation therapy of giant aggressive keratoacanthomas. Arch Dermatol 1993;129:1162-5.
7. Grob JJ, Suzini F, Richard MA, et al. Large keratoacanthomas treated with intralesional interferon alfa-2a. J Am Acad Dermatol 1993;29:237-41.
8. Yoshikawa K, Katagata Y, Kondo S. Relative amounts of keratin 17 are higher than those of keratin 16 in hair-follicle-derived tumors in comparison with nonfollicular epithelial skin tumors. 1995;104:396-400.
9. Ackerman AB. Histopathology of Keratoacanthoma. Philadelphia: W.B. Saunders, 1976.
10. Stavrianeas NG, Katoulis AC, Stratigeas NP, et al. Eruptive multiple keratoacanthomas of the extremities. Acta Derm Venereol 1998;78:228-9.
11. Schaller M, Korting HC, Wolff H, et al. Multiple keratoacanthomas, giant keratoacanthoma and keratoacanthoma centrifugum marginatum: development in a single patient and treatment with oral isotretinoin. Acta Derm Venereol 1996;76:40-2.
12. Hsi ED, Svoboda-Newman SM, Stern RA, et al. Detection of human papillomavirus DNA in keratoacanthomas by polymerase chain reaction. Am J Dermatopathol 1997;19:10-5.
13. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994;130:181-6.
14. Chuang TY, Reizner GT, Elpern DJ, et al. Keratoacanthoma in Kauai, Hawaii: the first documented incidence in a defined population. Arch Dermatol 1993;129:317-9.
15. Sullivan JJ. Keratoacanthoma: the Australian experience. Australas J Dermatol 1997;38(Suppl 1):S36-9.
16. Dufresne RG, Marrero GM, Robinson-Bostom L. Seasonal presentation of keratoacanthomas in Rhode Island. Br J Dermatol 1997;136:227-9.
17. Washington CV Jr, Mikhail GR. Eruptive keratoacanthoma en plaque in an immunosuppressed patient. J Dermatol Surg Oncol 1987;13:1357-60.
18. Borkowski A, Bennett WP, Jones RT, et al. Quantitative image analysis of p53 protein accumulation in keratoacanthomas. Am J Dermatopathol 1995;17:335-8.
19. Clausen OP, Beigi M, Bolund L, et al. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol 2002;119:1367-72.
20. Hu W, Cook T, Oh CW, et al. Expression of the cyclin-dependent kinase inhibitor p27 in keratoacanthoma. J Am Acad Dermatol 2000;42:473-5.
21. Kato N, Ito K, Kimura K, et al. Ferguson Smith type multiple keratoacanthomas and a keratoacanthoma centrifugum marginatum in a woman from Japan. J Am Acad Dermatol 2003;49:741-6.
22. Schwartz RA, Blaszczyk M, Jablonska S. Generalized eruptive keratoacanthoma of Grzybowski: follow-up of the original description and 50-year retrospect. Dermatology 2002;205:348-52.
23. Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 2004;30:326-33.
24. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994;30:1-19; quiz 20-2.
25. Pluzhnikov MS, Glukhova E, Nisrin MN, et al. Skin tumors of the face: experience in contact laser excision. Vestn Otorinolaringol 1995:15-20.
26. Neumann RA, Knobler RM. Argon laser treatment of small keratoacanthomas in difficult locations. Int J Dermatol 1990;29:733-6.
27. Landthaler M, Szeimies RM, Hohenleutner U, et al. Laser therapy of skin tumors. Recent Results Cancer Res 1995;139:417-21.
28. Lee WR, Shen SC, Lai HH. Transdermal drug delivery enhanced and controlled by erbium:YAG laser: a comparative study of lipophilic and hydrophilic drugs. J Control Release 2001;75:155-66.
29. Yun PL, Tachihara R, Anderson RR. Efficacy of erbium: yttrium-aluminum-garnet laser-assisted delivery of topical anesthetic. J Am Acad Dermatol 2002;47:542-7.
30. Capon A, Mordon S. Can thermal lasers promote skin wound healing? Am J Clin Dermatol 2003;4:1-12.
31. Kreisler M, Kohnen W, Marinello C., et al. Bactericidal effect of the Er:YAG laser on dental implant surfaces: an in vitro study. J Periodontol 2002;73:1292-8.
32. Ross EV, Naseef GS, McKinlay JR, et al. Comparison of carbon dioxide laser, erbium: YAG laser, dermabrasion, and dermatome: a study of thermal damage, wound contraction, and wound healing in a live pig model: implications for skin resurfacing. J Am Acad Dermatol 2000;42:92-105.
33. Greene D, Egbert BM, Utley DS, et al. In vivo model of histologic changes after treatment with the superpulsed CO(2) laser, erbium:YAG laser, and blended lasers: a 4- to 6-month prospective histologic and clinical study. Lasers Surg Med 2000;27:362-72.